Tecentriq Approved for Muscle-Invasive Bladder Cancer

Originally published by our sister publication Clinical Oncology NewsBy Jennifer KulpaThe FDA has approved atezolizumab (Tecentriq, Genentech) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) as adjuvant treatments for muscle-invasive bladder cancer (MIBC) after cystectomy in adults with circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.The agency also approved the Signatera CDx assay as a companion diagnostic to identify p